Results of Kamada’s Phase 2 Trial of Alpha-1 Antitrypsin in Newly Diagnosed Type-1 Diabetes Patients to be Presented at the Upcoming American Diabetes Association’s 78th Scientific Session...
Kamada Ltd. - Ordinary Shares (KMDA)
Last kamada ltd. - ordinary shares earnings: 2/12 07:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
kamada.com/investors.php
Company Research
Source: GlobeNewswire
REHOVOT, Israel, June 04, 2018 (GLOBE NEWSWIRE) -- Kamada Ltd. (Nasdaq:KMDA) (TASE:KMDA), a plasma-derived protein therapeutics company, today announced that the results from the Company’s Phase 2 trial of Alpha-1 Antitrypsin (AAT) in newly diagnosed type-1 diabetes (T1D) will be presented in an oral session at the 78th Scientific Sessions of the American Diabetes Association (ADA), which will be held from June 22-26, 2018, in Orlando, Florida. “We are excited to present the data from our Phase 2 trial of AAT in newly diagnosed T1D patients at such a prestigious medical conference,” said Amir London, Kamada’s Chief Executive Officer. “Based on the results generated to date, and feedback received from the medical community, we believe that further studies in a larger population are warranted. We are actively seeking the appropriate partner for the continued development of our T1D program.” Sunday, June 24, 2018, from 4:30 – 6:30 PM ET Session:From Progression to Management in Typ
Show less
Read more
Impact Snapshot
Event Time:
KMDA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
KMDA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
KMDA alerts
High impacting Kamada Ltd. - Ordinary Shares news events
Weekly update
A roundup of the hottest topics
KMDA
News
- Kamada Ltd. (NASDAQ:KMDA) Q4 2023 Earnings Call Transcript [Yahoo! Finance]Yahoo! Finance
- Kamada Reports Strong Fiscal Year and Fourth Quarter 2023 Financial Results, and Provides Full-Year 2024 Guidance Representing Double-Digit Growth in Revenue and Profitability [Yahoo! Finance]Yahoo! Finance
- Kamada Issues 2024 CEO Letter to ShareholdersGlobeNewswire
- Kamada Reports Strong Fiscal Year and Fourth Quarter 2023 Financial Results, and Provides Full-Year 2024 Guidance Representing Double-Digit Growth in Revenue and ProfitabilityGlobeNewswire
- Kamada to Announce Fourth Quarter and Fiscal Year 2023 Financial Results, and Provide 2024 Financial Guidance on March 6, 2024GlobeNewswire
KMDA
Earnings
- 3/6/24 - Beat
KMDA
Sec Filings
- 3/6/24 - Form 6-K
- 3/6/24 - Form 20-F
- 2/28/24 - Form 6-K
- KMDA's page on the SEC website